Novartis plans 46 MS abstracts: stock pre-market at EUR 127.29
Published on 10/08/2026 at 08:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
In a release dated October 7, 2026, GlobeNewswire reported that Novartis plans to present 46 abstracts from its multiple sclerosis portfolio at MSToronto2026. The company said the program will include late-breaking Phase III REMODEL-1 and REMODEL-2 results for remibrutinib.
Novartis stock was at EUR 127.29 in pre-market trading at Lang & Schwarz at 8:22 a.m. CEST on October 8, 2026. The bid was EUR 126.70 and the ask was EUR 127.88. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Novartis stock.
Multiple sclerosis program
The company said a second late-breaking abstract will present new data on Kesimpta, or ofatumumab, in pediatric multiple sclerosis. Additional presentations will cover treatment-naive patients with relapsing multiple sclerosis, breastfeeding-related data and pregnancy and infant outcomes. The release said the REMODEL results are scheduled for an oral presentation on October 23, while the pediatric NEOS study is also listed for an oral presentation that day. The company plans to hold a conference call for investors following the presentation of the REMODEL data, according to GlobeNewswire.
Investor event
The release described remibrutinib as an oral BTK inhibitor and said the investor event will provide updates on the data and the potential role of the medicine in multiple sclerosis. Novartis also said the wider program is intended to expand evidence for Kesimpta across different patient populations, including pediatric patients and people who are treatment-naive.
